Based on these data, Version 1.2024 of the NCCN Guidelines include T-DXd as a category 2A, useful in certain circumstances, 2L/subsequent therapy option for HER2-positive cervical cancer (IHC 3+/2+) (Abu-Rustum et al., 2023). This evidence concerns the gene ERBB2 and cervical cancer.